- First automated insulin delivery (AID) system in the world to
work with Abbott's FreeStyle Libre® 3 sensor
- Automated process streamlines and improves daily diabetes
management for people who are on insulin therapy1
- Hybrid closed-loop system mylife™ Loop incorporates
technology from two partners: CamDiab's algorithm automatically
adjusts insulin dosage on Ypsomed's insulin pump,
mylife™ YpsoPump®, based on
accurate2, real-time glucose information from FreeStyle
Libre 3 sensor
ABBOTT
PARK, Ill., Dec. 21,
2022 /PRNewswire/ -- Abbott (NYSE: ABT) today
announced that its FreeStyle Libre® 3 sensor is now
compatible with the mylife™ Loop solution from partners, Ypsomed
and CamDiab, creating a smart, automated process to deliver insulin
based on real-time glucose data. This automated insulin delivery
system (AID) solution is now available in Germany and will be available in additional
European countries beginning in 2023.
Advanced diabetes technologies, such as AID systems, are
designed to help people living with diabetes improve their glucose
control and reduce the burden of daily diabetes management.
Integrating CamDiab's CamAPS FX mobile app and Ypsomed's
mylifeTM YpsoPump® with
accurate2, real-time data from Abbott's FreeStyle Libre
3 sensor, the connected solution continuously monitors a person's
glucose levels, and automatically adjusts and delivers the right
amount of insulin at the right time, removing the guesswork of
insulin dosing and helping people with diabetes reach better
treatment targets.
"Our FreeStyle Libre portfolio is already helping to improve the
lives of 4.5 million people around the world who are living with
diabetes," said Jared Watkin, senior
vice president of Abbott's diabetes care business. "We're
partnering with diabetes and digital health technology leaders like
Ypsomed and CamDiab to deliver new innovative solutions that make
diabetes care as easy as possible, so people can spend less time
worrying about their diabetes and more time living."
According to JDRF's Type 1 Diabetes Index (T1D Index), the
average person living with Type 1 diabetes in Germany loses 18.5 healthy years when their
diabetes is not adequately managed. Healthy years lost represents
time lost to ill health, disability or other complications from
living with Type 1 diabetes. Nearly five healthy years could be
restored if they had access to devices that monitor glucose and
automate insulin delivery. Globally, 673,000 more people could be
alive in 2040 if everyone had access to technology that automates
glucose monitoring and insulin delivery.3
"As healthcare providers, one of the biggest challenges of
insulin therapy is when glucose levels get dangerously low," said
Dr. Rich Bergenstal, Executive Director of the International
Diabetes Center, HealthPartners Institute in Minneapolis, Minnesota. "Technological
innovations, like automated insulin delivery systems, can ease some
of that uncertainty by continuously monitoring a person's glucose
levels and delivering the right insulin dosage, which can
ultimately improve time in range. And better glucose control
reduces diabetes complications."
This AID solution is currently not available in the United States.
In addition to partnering with Ypsomed and CamDiab, Abbott is
working to make the FreeStyle Libre platform interoperable with
other leading insulin delivery systems.
About Abbott
Abbott is a global healthcare leader that
helps people live more fully at all stages of life. Our portfolio
of life-changing technologies spans the spectrum of healthcare,
with leading businesses and products in diagnostics, medical
devices, nutritionals and branded generic medicines. Our 113,000
colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at
www.linkedin.com/company/abbott-/, on Facebook at
www.facebook.com/Abbott and on Twitter @AbbottNews.
1 Automated Insulin Delivery: Benefits,
Challenges, and Recommendations. A Consensus Report of the Joint
Diabetes Technology Working Group of the European Association for
the Study of Diabetes and the American Diabetes Association,
October 2022.
https://doi.org/10.2337/dci22-0018
2 FreeStyle Libre 3 User's Manual. (7.5% MARD Adult;
8.6% MARD Pediatric)
3 JDRF Type 1 Diabetes (T1D) Index, September 2022.
https://www.t1dindex.org/germany
View original content to download
multimedia:https://www.prnewswire.com/news-releases/abbotts-freestyle-libre-3-integrated-with-automated-insulin-delivery-system-mylife-loop-in-germany-301707986.html
SOURCE Abbott